This market research report on RNAi covers both products and services in the RNAi industry. The global RNAi market is analyzed by Tools/Products and Applications for each of the geographic regions- United States, Europe , Asia-Pacific and Rest of World. The RNAi Tools/Products are further segmented into Design/Software (miRNA Target Scan, miRNA Analysis Software, and Design Software), Synthesis (Expression Vectors, Chemical, iRNA Isolation, Dicer/RNAseIII, and In Vitro), Delivery (Vector Based, Transfection Reagents, and Electroporation), Monitoring/Optimizing (Primers for RTqPCR, Controls, and miRNA Detection Tools), and Libraries (Human, Mouse, and Rat). Application by Research (Functional Genomics, Metabolism, and Protein Chemistry), Therapeutics (Oncology, Neurology, Ophthalmology, and Virology) and Drug Development (Target Identification, Target Validation, and Drug Mechanism) are also analyzed. Business profiles of 42 major companies are discussed in the research report. The research report serves as a guide to global RNAi industry covering 213 companies that are engaged in RNAi synthesis, R&D, therapeutics, test kits, tools and services. Major Research Organizations and Universities serving the industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, ethical issues, regulatory affairs, and other areas of concern is also covered in the research report. Projections and estimates are graphically illustrated by geographic, region with exclusive graphical representations provided for 384 exhibits.

Free Sample Research Report

Download Table of contents

The discovery of RNAi technology is the unpredicted outcome of experiments carried out on plants by a group of scientists in United States in early 1990s. RNAi was known through the years by various names such as quelling, gene silencing and transgene silencing. It was realized after a time that all these terms were describing the same phenomenon.

Antisense suppression of gene expression was not understood clearly and confused with RNAi. RNAi does not exhibit a catalytic affect in the degradation of mRNA. On the other hand it does involve singlestranded RNA fragments to bind with mRNA and in that process block translation. RNAi’s discovery has led to better understanding of gene control. The benefits of RNAi studies are huge and help regulating both the double-stranded RNA (already present and those produced). The development of an organism and its internal functions depend on its RNAi mechanism. RNAi can also block infected RNA viruses. Foreign elements in the genome can also be mutated. Hence, RNAi has revolutionized not only the study of genes but also its applications in the medical field. RNAi is already proven as a valuable tool in studying gene functions, in target identification and validation. siRNA applications have already demonstrated enormous cost and time benefits in these areas. The recent announcement by Novartis to have QIAGEN synthesize a complete human genome-wide siRNA library highlights the urgency on the pharmaceutical industry’s part to integrate RNAi into their drug development strategies and for therapeutic applications. Pharma and biotech companies are looking at RNAi as a key drug discovery tool. RNAi compounds are expected to hit the market atleast 5 years away. Clinical trials are underway and post efficacy in animals, huge investments are likely to trigger the RNAi market.

RNA interference, a term coined by Andy Fire and Craig Mello for their discovery which won them a Nobel Prize in 2006, is abbreviated as RNAi. It stands for the regulation mechanism of gene expression by RNA in living organisms. Andy Fire and Craig Mello worked on Ceonorhabditis elegans. RNAi is induced by miRNA/siRNA. These molecules, in association with RNA induced silencing complexes (RISC), bind to target mRNA and degrade it. There are other proteins involved in the accomplishment of this mechanism, which may differ in different organisms.

Prior to characterization, RNAi was known by other names such as gene silencing and post transcriptional transgene. It was only after the characterization at the molecular level it was recognized as the same phenomenon.

Global RNAi market is projected to grow at 25.6% compounded annually from 2005 to 2012. United States maintains its lead throughout. US and Europe are fore runners in RNAi based therapeutics. Asia-Pacific and Rest of World rank high in terms of CAGR.

Ambion, Dharmacon, Invitrogen and Qiagen continue to dominate the market for RNAi products. However their positions vary across market segments and geographic regions.Ambion, Invitrogen and Qiagen products are used equally in academia and industry, while Dharmacon is cited as a supplier far more frequently by industrial researchers than by academic researchers.

Numerous companies have sprung up capitalizing on the RNAi phenomenon. Pharma and biotech companies are looking at RNAi as a key drug discovery tool. RNAi compounds are expected to hit the market atleast 5 years away. Clinical trials are underway and post efficacy in animals, huge investments are likely to trigger the RNAi market. Collaborations, mergers, alliances, and licenses are expected to occur in a huge manner. In the coming years, market shares of the companies in RNAi products will majorly be driven by innovations in delivery tools, monitoring and optimizing aids, as a survey reveals dissatisfaction in these areas largely, while improvisations in design/software, synthesis and library tools will be an added advantage and give a better edge.

Countries Covered:
United States
Europe
Germany
United Kingdom
Belgium
France
Rest of Europe
Asia-Pacific
Australia
Japan
Rest of Asia-Pacific
Rest of World

For those who are intrested to buy the report by chapter:

CHAPTER	TITLE	SHORT DESCRIPTION	PRICE (US$)
I	Scope and Methodology	This chapter provides information regarding the research methodology, limitations of the study, market measuring units and exchange rates used. * Will be delivered free with purchase of any of the other chapters mentioned below.	FREE*
II	Report Synopsis	Synopsis of the report summarizes the global market of RNAi by Tools/Products and Application. Global market is also analyzed by geographic regions including the US , Europe , Asia-Pacific and rest of world.	$1200
III	Product / Technology Research	This chapter gives an insight into RNAi market including definitions, segmentation and applications. The chapter also provides market values in US$ (for the period 2005 through 2012) by Application (Research, Therapeutics, and Drug Development) and Tools/Products (Design/Software, Synthesis, Delivery, Monitoring/Optimizing, and Libraries). Global and regional markets are analyzed. The chapter also includes product trends, and potential opportunities.	$1100
IV	Market Dynamics	Market Dynamics provides information on global markets for RNAi. The chapter includes global market analysis by geographic regions; analysis of each region; a brief business profile of major global companies; and a glance at corporate activities such as mergers and acquisitions, partnerships, new product developments/launches etc. Also includes market trends and industry outlook.	$2350
V	Corporate Directory	This chapter provides a global region-wise list of 213 companies, CROs and academic institutions that are engaged in RNAi products and services.	$300